Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
CRVS
CRVS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CRVS News
Analysis of Corvus Pharmaceuticals Put Selling
Feb 02 2026
NASDAQ.COM
Momentum Is Beginning for These 3 Fast-Growing Stocks in 2026
Feb 02 2026
Marketbeat
Corvus Pharmaceuticals (CRVS) Stock Soars 211.8% to New All-Time High
Jan 26 2026
Yahoo Finance
Corvus Pharmaceuticals Upsizes Stock Offering to $175 Million for R&D and Working Capital
Jan 22 2026
stocktwits
Corvus Pharmaceuticals Prices $175M Upsized Public Offering to Fund Clinical Trials
Jan 22 2026
seekingalpha
Corvus Pharmaceuticals Prices Upsized Offering of 7.9 Million Shares at $22.15, Raising $175 Million
Jan 22 2026
Yahoo Finance
Netflix Reports Q4 Results, Q1 Guidance Misses Estimates
Jan 21 2026
Benzinga
Corvus Pharmaceuticals Initiates $150 Million Public Offering Amid 8.92% Stock Decline
Jan 21 2026
NASDAQ.COM
U.S. Stocks Plunge as Trump Revives Tariff Threats
Jan 21 2026
stocktwits
Corvus Pharmaceuticals Launches $150 Million Public Offering to Fund Clinical Trials
Jan 21 2026
stocktwits
Corvus Pharmaceuticals Soars 165.96% to $21.41 After Positive Eczema Data, Plans $150M Offering
Jan 21 2026
Fool
Corvus Pharmaceuticals Soars 166% on Eczema Data, Plans $150 Million Offering
Jan 21 2026
NASDAQ.COM
Corvus Pharmaceuticals Launches $150M Stock Offering to Fund R&D and Capital Expenditures
Jan 20 2026
seekingalpha
Corvus Pharmaceuticals Launches $150 Million Public Offering
Jan 20 2026
Yahoo Finance
Corvus Pharmaceuticals Reports Positive Soquelitinib Data, Stock Up 140%
Jan 20 2026
Benzinga
D.R. Horton Reports Q1 Net Income of $594.8M Exceeding Estimates
Jan 20 2026
Benzinga
Show More News
